Studies how long adults keep taking guselkumab for inflammatory bowel disease
Follows adults with ulcerative colitis or Crohn's disease who take guselkumab in routine care.
Plain-language title generated from the registry record
Registry title: A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi Arabia
Key facts
- Where
- Jeddah, Saudi ArabiaSee the site
Where in Saudi Arabia
- Al Salama HospitalJeddah, Saudi ArabiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Janssen Research & Development, LLC
- Trial code
- NCT07541261
- Record updated
- 2 July 2026
- Original description
The main purpose of this study is to evaluate treatment persistence of guselkumab (that is how long a person keeps taking their prescribed medicine or continues with their treatment plan without stopping) in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.Read full original descriptionShow less
A Multi-Center, Non-Interventional Study on Effectiveness and Treatment Persistence of Guselkumab in Patients With ULcerative Colitis and Crohn's DiseasE in Real-World Practice in Saudi Arabia
The main purpose of this study is to evaluate treatment persistence of guselkumab (that is how long a person keeps taking their prescribed medicine or continues with their treatment plan without stopping) in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.
Inclusion: The participant must be eligible for biologic treatment and initiate guselkumab according to the approved indications described in the current version of the summary of product characteristics (SmPC) approved in Saudi Arabia. The decision to prescribe must solely be made by the treating physician. Enrollment must take place before or at the day of first administration of guselkumab (but after treatment decision by physician) and after obtaining patient consent; The participant must have a confirmed diagnosis of moderate-to-severe CD or UC recorded in their medical records; The participant must sign a participation agreement/informed consent form (ICF) allowing source data verification.
Exclusion: Has been previously exposed to Interleukin (IL)-23 inhibitors, including tremfya (guselkumab), skyrizi (risankizumab) and omvoh (mirikizumab). As an exception, participants with history of ustekinumab exposure may be included; History of more than 4 lines of advanced inflammatory bowel disease (IBD) therapy (biologics and/or small molecules); Contraindicated to guselkumab per the label; Is currently enrolled in an interventional clinical study; Is unable to provide informed consent.